SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Ethereum is a global, open-source platform for decentralized applications. In other words, it is a decentralized blockchain platform that enables developers to build and deploy smart contracts and applications without central authority control. Unlike Bitcoin, which primarily functions as digital currency, Ethereum operates as a programmable global computer where developers can create any type of decentralized service.   The platform hosts over $14 billion in DeFi applications with hundreds of thousands of active users across financial protocols, NFT marketplaces, and gaming platforms. Its transition to Proof of Stake in September 2022 reduced energy consumption by over 99%, addressing environmental concerns while strengthening network security.  The network operates through thousands of independent validator nodes that process transactions and execute smart contracts on the Ethereum Virtual Machine. Smart contracts are self-executing programs written in Solidity that automatically carry out agreements when conditions are met, eliminating intermediaries like banks or brokers.   Validators stake ETH as collateral to propose and validate blocks, earning rewards for honest participation while facing penalties for malicious behavior. The EIP-1559 upgrade introduced a dynamic base fee mechanism that burns ETH with each transaction, creating deflationary pressure during high network activity when more ETH is burned than issued to validators.  Vitalik Buterin proposed Ethereum in 2013, but seven co-founders helped build it, including Gavin Wood who created Solidity and the EVM technical specification, and Joseph Lubin who founded ConsenSys. The project launched in July 2015 after raising over $18 million through crowdfunding, quickly becoming the largest blockchain developer community. Major milestones include the 2020 Beacon Chain launch, the 2021 London hard fork implementing fee burning, and the 2022 Merge to Proof of Stake.   Ether (ETH) serves multiple functions: paying transaction fees (gas), staking to secure the network and earn 3-5% annual yields, serving as collateral in DeFi protocols, and purchasing NFTs and digital assets. The asset is increasingly adopted by traditional institutions, with publicly traded companies adding ETH to corporate treasuries to generate staking yields while maintaining blockchain exposure, and in 2024, the SEC approved spot Ethereum ETFs, allowing traditional investors to gain exposure through conventional brokerage accounts.  Ethereum's roadmap focuses on dramatically increasing transaction capacity to over 100,000 per second, reducing confirmation times, and enhancing decentralization while maintaining security against future threats like quantum computing.

Ethereum

Ethereum is drawing significant attention for its strong network fundamentals, including rising staking demand and its growing role as infrastructure for AI agents and financial applications. The community is debating its resilience amidst market volatility, with ongoing institutional interest and ETF inflows contrasting with concerns about price manipulation.

Based Chad

CHAD CRYPTO is trending as community enthusiasm surges, driven by prominent Coinbase executives and the Base lead developer actively supporting the token's ecosystem, which includes unique buyback and staking features, further solidifying its appeal as a universally recognized meme.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is actively trending following the FDA approval of Nereus for motion sickness, with community attention now shifting to its blockbuster potential for GLP-1 induced nausea and the highly anticipated Bysanti PDUFA decision in February. Investors are debating the company's undervalued status and the likelihood of a major buyout or partnership driven by these significant pipeline developments.

The Cosmos network consists of many independent, parallel blockchains, called zones, each powered by classical Byzantine fault-tolerant (BFT) consensus protocols like Tendermint. Some zones act as hubs with respect to other zones, allowing many zones to interoperate through a shared hub. The architecture uses classic BFT and Proof-of-Stake algorithms, instead of Proof-of-Work. Cosmos can interoperate with multiple other applications and cryptocurrencies, something other blockchains can’t do well. By creating a new zone, you can plug any blockchain system into the Cosmos hub and pass tokens back and forth between those zones, without the need for an intermediary.  While the Cosmos Hub is a multi-asset distributed ledger, there is a special native token called the atom. ATOM have three use cases: as a spam-prevention mechanism, as staking tokens, and as a voting mechanism in governance.  As a spam prevention mechanism, ATOM are used to pay fees. The fee may be proportional to the amount of computation required by the transaction, similar to Ethereum’s concept of “gas”. Fee distribution is done in-protocol and a protocol specification is described here.  As staking tokens, ATOM can be “bonded” in order to earn block rewards. The economic security of the Cosmos Hub is a function of the amount of ATOM staked. The more ATOM that are collateralized, the more “skin” there is at stake and the higher the cost of attacking the network. Thus, the more ATOM there are bonded, the greater the economic security of the network.  Atom holders may govern the Cosmos Hub by voting on proposals with their staked ATOM.

Cosmos

The Cosmos (ATOM) community is actively engaged in discussions surrounding a significant tokenomics redesign, proposing a shift from inflationary rewards to a revenue-based model to enhance its long-term sustainability. Holders, many attracted by high staking yields, maintain belief in ATOM's core utility as the "Internet of Blockchains" and anticipate a rebound within broader cryptocurrency market movements.

Permian Resources Holdings, Inc. engages in the exploration and production of oil and natural gas. It also focuses on driving sustainable returns through the responsible acquisition, optimization, and development of crude oil. The company was founded on October 6, 2014 and is headquartered in Midland, TX.

Permian Resources Holdings Inc. - Ordinary Shares - Class A

Permian Resources Corp - Ordinary Shares - Class A

Permian Resources is trending as the community debates the broader energy sector outlook, with recent analyst upgrades and strong operational fundamentals, including strategic acquisitions and consistent dividends, often contrasted against persistent oil price volatility and global supply concerns.

Pump Mind Virus is a Pure Meme with a long term vision. We are building for the future while making no promises about the present. The project aims to bring the spirit of community memes back to the Solana ecosystem. We do that with engaging content and memes. Culture through community. Viral spread by word of mouth.  And most importantly, by not using the fake hype machine that has come to dominate the meme coin landscape.

PumpMindVirus

PMV Crypto is trending as its community, driven by "total conviction" and "bullish vibes," rallies around the belief that the "bottom is in" for this "pure meme" coin on Solana, actively pushing its "viral agenda" for future growth and a "next Pepe" status.

Polkadot is a platform that allows diverse blockchains to transfer messages, including value, in a trust-free fashion; sharing their unique features while pooling their security. In brief, Polkadot is a scalable heterogeneous multi-chain technology.  Polkadot is heterogeneous because it is entirely flexible and makes no assumption about the nature or structure of the chains in the network. Even non-blockchain systems or data structures can become parachains if they fulfill a set of criteria.  Polkadot may be considered equivalent to a set of independent chains (e.g. a set containing Ethereum, Ethereum Classic, Namecoin and Bitcoin) except with important additions: pooled security and trust-free interchain transactability.  Many of the native parachains of Polkadot will be written using a Polkadot Runtime Environment SDK (e.g. Parity Technologies' Substrate).

Polkadot

Polkadot (DOT) is trending as its ecosystem undergoes significant changes with the rollout of Polkadot 2.0, enhancing network utility through features like Agile Coretime. The community is actively discussing the recent pivotal approval of a 2.1 billion token supply cap and halving emissions, a fundamental shift that bulls see as a strong catalyst for future value, despite lingering skepticism over its historical price action.

The Compound Governance Token is a governance token on the Compound Finance lending protocol, COMP allows the owner to delegate voting rights to the address of their choice; the owner’s wallet, another user, an application, or a DeFi expert. Anybody can participate in Compound governance by receiving delegation, without needing to own COMP.  Anybody with 1% of COMP delegated to their address can propose a governance action; these are simple or complex sets of actions, such as adding support for a new asset, changing an asset’s collateral factor, changing a market’s interest rate model, or changing any other parameter or variable of the protocol that the current administrator can modify.

Compound

Compound (COMP) is trending due to anticipation surrounding its V4 roadmap, potential fintech partnerships, and its maxed-out token supply which bulls believe could lead to a significant price appreciation. However, the community remains divided, with skeptics highlighting past underperformance and ongoing governance concerns.

Realty Income Corp. is a real estate company, which engages in generating dependable monthly cash dividends from a consistent and predictable level of cash flow from operations. The company was founded by William E. Clark, Jr. and Evelyn Joan Clark in 1969 and is headquartered in San Diego, CA.

Realty Income Corp.

Realty Income ($O) is garnering significant attention following a Deutsche Bank upgrade to Buy with a raised price target, coupled with news of a substantial $1.5B joint venture with GIC. The community is actively discussing its appeal as a stable monthly dividend stock and a potential hedge in uncertain markets, with many anticipating further appreciation amid expectations of future interest rate cuts.

LightPath Technologies, Inc. engages in the design, development, manufacture, and distribution of optical and infrared components. Its products include molded glass and assemblies, infrared molded lenses, diamond turned, conventional ground and polished ground lenses and assemblies, and collimator assemblies, which are used in applications involving light detection and ranging technology. The firm supports a range of customers in the field of industrial, laser, defense, medical, telecommunications, and instrumentation. The company was founded in1985 and is headquartered in Orlando, FL.

Lightpath Technologies, Inc. - Ordinary Shares - Class A

Lightpath Technologies is trending on record Q2 revenue and a $9.6 million defense order, with investors keenly focused on its strategic Amorphous Materials acquisition expanding BlackDiamond optics and the highly anticipated NGSRI missile contract, positioning the company for significant growth in the defense sector.

statis crypto Watchlist

Bitcoin

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

TG Therapeutics, Inc. $TGTX Shares Bought by Public Sector Pension Investment Board

Public Sector Pension Investment Board lifted its holdings in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 14.5% during the 3rd quarter, according to its most recent 13F filing with the...

TG Therapeutics, Inc. (NASDAQ:TGTX) Receives Average Rating of "Moderate Buy" from Brokerages

TG Therapeutics, Inc. (NASDAQ:TGTX - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the six brokerages that are presently covering the company, Marketbeat reports...

TG Therapeutics (NASDAQ:TGTX) Downgraded by Wall Street Zen to "Hold"

Wall Street Zen cut TG Therapeutics from a "buy" rating to a "hold" rating in a report on Saturday...

<ul class="summary-bullets"><li>TG Therapeutics launched the NextInMS platform to support people living with multiple sclerosis.</li><li>Briumvi remains the key growth driver, with the company guiding to $825 million to $850 million in global revenue from the drug in 2026.</li><li>Wall Street sees upside, with JPMorgan and Goldman Sachs pointing to roughly 59% and 35% upside, respectively, from the stock’s last close.</li></ul>TG Therapeutics, Inc. sparked heightened retail chatter on Monday after unveiling a new multiple sclerosis (MS) awareness collaboration with Christina Applegate, which debuted during Super Bowl LX.<h2 class="st-heading-2">TG Launches NextInMS Platform</h2>The company launched NextInMS.com, a new platform designed to encourage open and informed conversations among people living with MS, caregivers, and healthcare professionals.Applegate, who has been living with MS for five years, is leading the campaign and will share personal perspectives on navigating the disease and making long-term decisions. TG Therapeutics said the platform will also feature educational content from MS experts.<h2 class="st-heading-2">Briumvi Fuels 2026 Growth Outlook</h2>The campaign comes as TG Therapeutics continues to build momentum around Briumvi, its approved treatment for relapsing forms of multiple sclerosis. The company reported preliminary full-year 2025 global revenue of about $616 million, driven largely by Briumvi, which generated $594 million in U.S. net product revenue. Fourth-quarter U.S. net product revenue was estimated at roughly $182 million.The company also guided to a full-year 2026 total global revenue of $875 million to $900 million, including $825 million to $850 million in U.S. net product revenue from Briumvi. The company said it expects growth to be supported by ongoing commercial execution and efforts to further improve treatment convenience.Last year, TG Therapeutics completed enrollment in the Phase 3 Enhance trial evaluating a simplified intravenous dosing schedule for Briumvi, with topline data expected in mid-2026. The company also plans to announce pivotal topline data for a self-administered subcutaneous formulation around year-end 2026 or early 2027, alongside additional exploratory studies that could expand Briumvi’s use beyond multiple sclerosis.TG Therapeutics' six-year results showed that nearly 90% of patients on continuous Briumvi treatment remained free from disability progression, with a low annualized relapse rate and no new safety signals reported over extended follow-up.<h2 class="st-heading-2">Wall Street Sees Upside In TGTX Stock</h2>Earlier this month, JPMorgan lowered its price target on TG Therapeutics to $46 from $49, implying a 59% upside from the stock’s last close, while maintaining an ‘Overweight’ rating.&nbsp;On the other hand, Goldman Sachs raised its price target to $39 from $37, implying a 35% upside from current levels, and reiterated a ‘Neutral’ rating. The brokerage pointed to the company’s 2026 revenue guidance and progress in the Briumvi program.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for TGTX was ‘bullish’ amid ‘normal’ message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/tgtx_ss_png_fa811bf158.webp" alt="tgtx ss.png" width="972" height="139"><figcaption>TGTX sentiment and message volume as of February 9 | Source: Stocktwits</figcaption></figure>One user said, “TG actually partnered with Christina Applegate. She brings her authentic lived experience, it will expand brand visibility more than ever, build MORE trust with patients and providers, and will support B organically. Huge win for TG. If MW wanted to, its an easy sale from here..”<stembedurl>https://stocktwits.com/Insidersknow/message/644419693</stembedurl>Another user speculated that greater visibility around Christina Applegate’s treatment experience with TG Therapeutics could further boost the stock, saying, “TG rockets with even more impressive sales.”<stembedurl>https://stocktwits.com/PotionX1900/message/644429350</stembedurl><a href="https://stocktwits.com/symbol/TGTX">TGTX stock</a> has declined 14% over the past 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Christina Applegate (L) speaks onstage during the Light Up The Blues 7 Concert celebrating Autism Speaks' 20th Anniversary at the Greek Theatre on April 26, 2025 in Los Angeles, California. (Photo by Kevin Winter/Getty Images)

TG Therapeutics Lights Up Super Bowl With Christina Applegate MS Campaign — Retail Sees 'Huge Win'

TG Therapeutics reported that six-year data showed nearly 90% of patients on continuous Briumvi remained free of disability progression.

Equity

Universal Beteiligungs und Servicegesellschaft mbH Has $2.29 Million Stake in TG Therapeutics, Inc. $TGTX

Universal Beteiligungs und Servicegesellschaft mbH lessened its holdings in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 67.1% during the third quarter, according to the company in...

Shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Get Free Report) have received a consensus rating of "Moderate Buy" from the six brokerages that are currently covering the company, MarketBeat reports...

Q4 EPS Estimates for TG Therapeutics Raised by HC Wainwright

TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) - Stock analysts at HC Wainwright raised their Q4 2025 earnings per share estimates for TG Therapeutics in a research report issued to clients and...

TG Therapeutics (NASDAQ:TGTX) Trading 7.5% Higher - Here's Why

TG Therapeutics (NASDAQ:TGTX) Stock Price Up 7.5% - Here's What Happened...

HC Wainwright Forecasts TG Therapeutics FY2025 Earnings

TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) - Stock analysts at HC Wainwright raised their FY2025 EPS estimates for TG Therapeutics in a research report issued to clients and investors on...

Currency and Exchange Stock Chart for Finance and Economy Display. (Image Courtesy: Getty Images)

TG Therapeutics Stock Pops As Briumvi Boom Reignites Bull Case: Goldman Sachs Sees Room For 32% Rally

Strong 2026 guidance and accelerating uptake of its MS drug send TGTX to its best session in months, with Wall Street and retail piling in.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

3%+ above current levels

Up 0–3%

Flat to down 3%

Down 3%+

The Nasdaq 100 continues to hinge on mega-cap tech and AI strength. With rate expectations shifting and valuations stretched, even a 3% move could signal a bigger trend. Is momentum building, or fading?

Current Price	$28.44
Prev Close	$28.42
Open	$28.73
Dividend Yield	0.00%
50-Day Moving Average	$30.18
Beta	1.06
Avg. Volume	2.5M
PE Ratio	10.23

52-Week High	$46.48
52-Week Low	$25.28
Market Capitalization	$4.51B
EPS (Annual)	$0.1458
Price to Book	7.26
Revenue Per Employee	$973,384.61

TGTX
TG Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest TGTX News

TGTXTG Therapeutics Inc